Publication: Tumor Surface Regularity at MR Imaging Predicts Survival and Response to Surgery in Patients with Glioblastoma.
No Thumbnail Available
Identifiers
Date
2018
Authors
Pérez-Beteta, Julián
Molina-García, David
Ortiz-Alhambra, José A
Fernández-Romero, Antonio
Luque, Belén
Arregui, Elena
Calvo, Manuel
Borrás, José M
Meléndez, Bárbara
Rodríguez de Lope, Ángel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Purpose To evaluate the prognostic and predictive value of surface-derived imaging biomarkers obtained from contrast material-enhanced volumetric T1-weighted pretreatment magnetic resonance (MR) imaging sequences in patients with glioblastoma multiforme. Materials and Methods A discovery cohort from five local institutions (165 patients; mean age, 62 years ± 12 [standard deviation]; 43% women and 57% men) and an independent validation cohort (51 patients; mean age, 60 years ± 12; 39% women and 61% men) from The Cancer Imaging Archive with volumetric T1-weighted pretreatment contrast-enhanced MR imaging sequences were included in the study. Clinical variables such as age, treatment, and survival were collected. After tumor segmentation and image processing, tumor surface regularity, measuring how much the tumor surface deviates from a sphere of the same volume, was obtained. Kaplan-Meier, Cox proportional hazards, correlations, and concordance indexes were used to compare variables and patient subgroups. Results Surface regularity was a powerful predictor of survival in the discovery (P = .005, hazard ratio [HR] = 1.61) and validation groups (P = .05, HR = 1.84). Multivariate analysis selected age and surface regularity as significant variables in a combined prognostic model (P
Description
MeSH Terms
Brain
Brain Neoplasms
Female
Glioblastoma
Humans
Kaplan-Meier Estimate
Magnetic Resonance Imaging
Male
Middle Aged
Predictive Value of Tests
Survival Analysis
Treatment Outcome
Brain Neoplasms
Female
Glioblastoma
Humans
Kaplan-Meier Estimate
Magnetic Resonance Imaging
Male
Middle Aged
Predictive Value of Tests
Survival Analysis
Treatment Outcome